Last reviewed · How we verify
Tetravalent live attenuated dengue vaccine
Tetravalent live attenuated dengue vaccine is a Biologic drug developed by U.S. Army Medical Research and Development Command. It is currently in Phase 1 development.
At a glance
| Generic name | Tetravalent live attenuated dengue vaccine |
|---|---|
| Sponsor | U.S. Army Medical Research and Development Command |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge (PHASE1)
- Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases (PHASE4)
- A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan (PHASE2, PHASE3)
- A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India (PHASE3)
- A Study in Children and Adolescents on the Effectiveness of Takeda's Licensed Dengue Vaccine TDV Against Hospitalization Due to Dengue Disease
- A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers (PHASE3)
- Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose (PHASE3)
- ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetravalent live attenuated dengue vaccine CI brief — competitive landscape report
- Tetravalent live attenuated dengue vaccine updates RSS · CI watch RSS
- U.S. Army Medical Research and Development Command portfolio CI
Frequently asked questions about Tetravalent live attenuated dengue vaccine
What is Tetravalent live attenuated dengue vaccine?
Tetravalent live attenuated dengue vaccine is a Biologic drug developed by U.S. Army Medical Research and Development Command.
Who makes Tetravalent live attenuated dengue vaccine?
Tetravalent live attenuated dengue vaccine is developed by U.S. Army Medical Research and Development Command (see full U.S. Army Medical Research and Development Command pipeline at /company/u-s-army-medical-research-and-development-command).
What development phase is Tetravalent live attenuated dengue vaccine in?
Tetravalent live attenuated dengue vaccine is in Phase 1.